Alison J. Moskowitz, MD, discusses the latest treatment advances across subtypes of lymphoma.
Paul K. Paik, MD, discusses treatment advances and sequencing strategies for patients with ALK-positive NSCLC.
C. Ola Landgren, MD, PhD, shares his insight on CAR T-cell therapy, sequencing, and triplet and quadruplet regimens in myeloma.
Paul R. Helft, MD, discusses the incidence of gastrointestinal neuroendocrine tumors and available and emerging treatment methods.
Helena A. Yu, MD, discusses sequencing strategies in EGFR-mutant NSCLC, the impact of osimertinib in the frontline setting, and the questions surrounding dacomitinib’s intriguing data in this landscape.
Koen van Besien, MD, PhD, shares his insights on challenges with bone marrow transplant and on the potential future for these technologies in a time when the landscape is undergoing many changes.
Tanios Bekaii-Saab, MD, sheds light on the recent advances in the treatment of patients with hepatocellular carcinoma.
Matthew D. Hellmann, MD, discusses the expansion of biomarkers across single-agent and combination therapies in patients with non–small cell lung cancer.
Nadine M. Tung, MD, discusses the role of PARP inhibitors for patients with BRCA-positive breast cancer and the importance of genetic testing.
An interim analysis revealed that the immunotherapy rocapuldencel-T is unlikely to meet any of the primary endpoints of the phase III ADAPT trial in patients with metastatic renal cell carcinoma.